Abeona Therapeutics Inc Transmettre P/E
Quel est le Transmettre P/E de Abeona Therapeutics Inc?
Le Transmettre P/E de Abeona Therapeutics Inc est -1.35
Quelle est la définition de Transmettre P/E?
Le ratio prix à terme/bénéfice est le rapport entre le prix des actions d'une société et son bénéfice par action estimé pour les douze prochains mois.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Transmettre P/E des entreprises dans Health Care secteur sur NASDAQ par rapport à Abeona Therapeutics Inc
Que fait Abeona Therapeutics Inc?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Entreprises avec transmettre p/e similaire à Abeona Therapeutics Inc
- Editas Medicine Inc a Transmettre P/E de -1.41
- Torstar a Transmettre P/E de -1.40
- Sutro Biopharma Inc a Transmettre P/E de -1.38
- Genprex Inc a Transmettre P/E de -1.37
- LL Flooring Inc a Transmettre P/E de -1.36
- CHF Solutions Inc a Transmettre P/E de -1.36
- Abeona Therapeutics Inc a Transmettre P/E de -1.35
- Spero Therapeutics Inc a Transmettre P/E de -1.35
- Aerpio Pharmaceuticals a Transmettre P/E de -1.34
- Bionano Genomics Inc a Transmettre P/E de -1.32
- Bio-Path Inc a Transmettre P/E de -1.29
- Chimerix Inc a Transmettre P/E de -1.29
- DBV Technologies SA a Transmettre P/E de -1.29